Iovance Biotherapeutics (IOVA) News Today

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) rose sharply after raising its full-year 2026 revenue outlook, with demand for its cancer therapies driving renewed investor optimism. The stock is trading near its 52-week high and well above its 50-day and 200-day moving averages, reflecting strong momentum.

• Positive Sentiment: Iovance raised 2026 revenue guidance to $410 million-$420 million, up from $350 million-$370 million previously and above analyst estimates near $402 million. Management cited strong U.S. demand for Amtagvi (lifileucel) and Proleukin, providing the primary catalyst for the stock’s advance. Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
• Positive Sentiment: The outlook increase suggests commercial traction for Iovance’s melanoma treatment portfolio and supports expectations for continued revenue growth. Reports highlighted strong melanoma-drug demand and an anticipated increase of roughly 60% in revenue. Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth
• Positive Sentiment: HC Wainwright raised its price target from $9 to $20 and maintained a Buy rating, implying additional upside based on the referenced $14.45 share price. The higher target reflects greater confidence in Iovance’s commercial turnaround.
• Positive Sentiment: The shares advanced more than 30% on unusually heavy volume and reached their highest level since 2024, indicating that the guidance update attracted substantial market participation. Iovance hits highest since 2024 as analysts cheer guidance raise
• Neutral Sentiment: Despite the stronger revenue outlook, Iovance remains unprofitable, and its valuation now reflects substantial expectations for continued execution.
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revisions may not support further near-term gains. Another analysis argued that much of the turnaround may already be priced in and downgraded the stock to Hold, creating a potential consolidation risk after the sharp rally. Iovance Biotherapeutics Surges: Is This an Indication of Further Gains?